Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria.

ABSTRACT:

Background

Despite the widespread use and availability of rapidly acting anti-malarials, the fatality rate of severe malaria in sub-Saharan Africa remains high. Adjunctive therapies that target the host response to malaria infection may further decrease mortality over that of anti-malarial agents alone. Peroxisome proliferator-activated receptor-gamma agonists (e.g. rosiglitazone) have been shown to act on several pathways implicated in the pathogenesis of severe malaria and may improve clinical outcome as an adjunctive intervention.

Methods

In this study, the safety and tolerability of adjunctive rosiglitazone in paediatric uncomplicated malaria infection was evaluated in Mozambique, as a prelude to its evaluation in a randomized controlled trial in paediatric severe malari

SUBMITTER: Varo R 

PROVIDER: S-EPMC5442675 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature